Clinical Trial · NCT07925125

Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer Lesions

Overview

Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis, and early detection of pancreatic lesions is of great importance for improving patient outcomes. In this study, whole-body imaging with FDG and FAPI will be used to visualize the early development of pancreatic cancer lesions from multiple perspectives, including glucose metabolism, tumor fibrotic stroma, and integrin receptor expression. Furthermore, leveraging the advantages of four-dimensional dynamic long-axial PET imaging, artificial intelligence-assisted lesion detection and analysis will be performed to characterize lesions and differentiate between benign and malignant lesions. The imaging findings will subsequently be compared with postoperative histopathological results to evaluate the diagnostic performance of the proposed imaging approaches.

Sponsor

Ruijin Hospital

ClinicalTrials.gov

NCT07925125

Drug / Compound

FDG

Isotope(s):
Target(s):
  • HK2
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Histopathological diagnosis obtained through surgery or biopsy within 2 months after PET imaging.
  • Willing and able to comply with the study procedures and follow-up requirements.
  • No prior treatment for the suspected pancreatic tumor.
  • In generally good health, with an estimated life expectancy of more than 6 months and able to tolerate the imaging procedures.
  • Patients with suspected pancreatic tumors larger than 1.0 cm.
  • No histopathological diagnosis available before enrollment.

Exclusion

  • Poor compliance with the study procedures.
  • Pregnancy, suspected pregnancy, or breastfeeding.
  • Severe concomitant diseases that, in the investigator's judgment, make participation in the study inappropriate, including severe cardiopulmonary dysfunction or severe hepatic or renal impairment.